BSF Enterprise PLC
25 August 2026
25 August 2026
BSF Enterprise PLC
("BSF" or the "Company")
Conversion of Convertible Loan Notes
BSF Enterprise Plc (LSE: BSFA), (OTCQB: BSFAF), the biotechnology company focused on tissue engineering, lab-grown materials and bioactive solutions, announces that it has received a notice from Indigo Capital Investments ("Indigo") to convert £100,283 of the outstanding amount of £1m under the Company's convertible loan note instrument (the "CLN").
Accordingly, the Company will issue 10,000,000 new ordinary shares of 1 penny each to Indigo (the "Conversion Shares") in satisfaction of £100,283 of the outstanding amount under the CLN.
Admission and Total Voting Rights
Application will be made for the Conversion Shares to be admitted to the Equity Shares (transition) category of the Official List and to trading on the London Stock Exchange's main market for listed securities ("Admission"). Admission is expected to become effective and dealings in the Conversion Shares to commence at 8.00 a.m. on 28 August 2026.
The Conversion Shares will rank pari passu in all respects with the Company's existing ordinary shares.
Following Admission, the Company's issued share capital and total voting rights will comprise 203,749,437 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310).
Navigate to our Interactive Investor website here: https://bsfenterprise.com/link/r6w2wP
For further enquiries, please visit www.bsfenterprise.com or contact:
|
BSF Enterprise PLC Geoff Baker - Chairman Che Connon - CEO & Director We encourage all investors to share questions on this announcement via our investor website. |
|
|
Bowsprit Partners John Treacy James Sheehan |
+44 (0)203 883 4430 |
|
ISIN of the Ordinary Shares is GB00BHNBDQ51. SEDOL Code is BHNBDQ5. |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.